NCT06199895View on ClinicalTrials.gov

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 28, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Pancreatic AdenocarcinomaCholangiocarcinomaLung CancerStomach CancerEsophageal CarcinomaBreast Cancer
Interventions
DRUG

Paclitaxel Polymeric Micelles for Injection

300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for ≥ 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.

Trial Locations (1)

430030

RECRUITING

Tongji Hospital, Wuhan

All Listed Sponsors
lead

Liu Huang

OTHER